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Summary: In HAN 345 (http://emergency.cdc.gov/HAN/han00345.asp), April 2013, CDC reported that 
TUBERSOL®, a product o f Sanofi Pasteur Limited, was in shortage nationwide. Although supplies were 
restored in early June 2013, TUBERSOL® is in shortage again until at least the middle o f October 2013. 
At the current time, the 5 tuberculin units/0.1 mL, 5 mL (50 tests), multiple dose vials are unavailable. The 
5 tuberculin units/0.1 mL, 1 mL (10 tests), multiple dose vials are in limited supply. This notice updates 
and supersedes the advice in HAN 345 and advises public health officials, clinicians, and workers 
in occupational health and infection control about how to adapt testing protocols to the recurrent 
shortage.
TUBERSOL® is one o f two purified-protein derivative (PPD) tuberculin antigen solutions that are licensed 
by the United States Food and Drug Administration (FDA). JHP Pharmaceuticals, LLC, manufactures 
APLISOL®, the other PPD tuberculin product that is licensed by FDA. JHP Pharmaceuticals, LLC, has 
notified FDA that APLISOL® is on allocation, meaning that historical customers have precedence for 
buying the product, and APLISOL® is available in restricted quantity. Regional shortages o f APLISOL®  
have been reported since healthcare providers switched from TUBERSOL® to APLISOL®.
Background
Two kinds of immunological methods are used for detecting Mycobacterium tuberculosis infection: 
tuberculin skin tests (TSTs) and interferon-y release assay (IGRA) blood tests. The indications for using 
these tests are the same for both methods, although one or the other method is preferred for certain 
populations (1). When setting testing priorities because of the current shortage of antigen, these 
preferences may be considered as factors when one of the methods is unavailable. Together, these tests 
are the only means for detecting latent M. tuberculosis infection, and they contribute to diagnosing 
tuberculosis (TB) disease. When findings such as chest radiography and mycobacterial cultures are 
sufficient for confirming or excluding the TB diagnosis, the results from a TST or an IGRA blood test might 
be unnecessary (2). Nevertheless, most TB cases in the United States are diagnosed with a set of 
findings including results from one of these tests. When TB disease is strongly suspected, specific 
treatment should be started regardless of results from TST or an IGRA blood test (1,3).
In cross-sectional controlled studies, TUBERSOL® and APLISOL® give similar results for most patients. 
The agreement between results from a TST and an IGRA blood test or between results from the two 
commercial IGRA blood tests is lower (1).
Recommendations
CDC recommends any of three general approaches for addressing the shortages of tuberculin skin test 
antigens:
1. Substitute IGRA blood tests for TSTs. The cost associated with using the blood tests can be greater 
than the cost of TST because the per-unit cost of the IGRA test materials is greater than for those of TST 
and, unlike TST, IGRAs entail services external to the point of care in some settings. The blood tests 
require phlebotomy, preparation of blood specimens, and specific laboratory services for analysis; 
therefore, these tests are not available in all practice settings. Clinicians who use the IGRA blood tests 
should be aware that the criteria for test interpretation are different from the criteria for interpreting TSTs 
(1). IGRAs do not utilize the risk-stratified cut-off measurements that are used for TST. Both IGRA 
products that are licensed in the United States can give indeterminate results, and one of these can also 
give borderline results (results between positive and negative). TST does not yield indeterminate or 
borderline results (1).
2. Substitute APLISOL® for TUBERSOL® for skin testing if APLISOL® is available. In studies, the two 
products give similar results for most patients. The fixed availability of APLISOL® has created a relative 
shortage because of increased demand at sites where TUBERSOL® is unavailable, thus limiting the 
feasibility of this approach.
3. Allocate TSTs to priority usages, such as TB contact investigations, as determined by public health 
authorities. Priorities can be set in accordance to relative TB risks (4) and local TB epidemiology. A 
priority strategy might require deferment of testing some persons, and it might require modification of 
public health rules, regulations, or policies. CDC does not recommend testing persons who are not at risk 
for TB (4).
Some surveillance programs for TB infection control rely on routine serial TSTs. Switching products or 
methods might make serial changes in test results difficult to interpret. The apparent conversions of 
results from negative to positive or reversions from positive to negative could be caused by inherent inter­
product or inter-method discordance (1,5). In settings with a low likelihood of TB exposure, the deferment 
of routine serial testing should be considered in consultation with public health and occupational health 
authorities.
Updates about the shortages of tuberculin skin test solutions are posted by the FDA Center for Biologics 
Evaluation and Research at
http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Shortages/ucm351921 .htm.
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The Centers fo r  Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national, and international
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